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ABSTRACT
A series of multi-target directed edaravone derivatives bearing N-benzyl pyridinium moieties were
designed and synthesised. Edaravone is a potent antioxidant with significant neuroprotective effects and
N-benzyl pyridinium has previously exhibited positive results as part of a dual-site binding, peripheral
anionic site (PAS) and catalytic anionic site (CAS), acetylcholinesterase (AChE) inhibitor. The designed edar-
avone-N-benzyl pyridinium hybrid compounds were docked within the AChE active site. The results indi-
cated interactions with conserved amino acids (Trp279 in PAS and Trp84 in CAS), suggesting good dual-
site inhibitory activity. Significant in vitro AChE inhibitory activities were observed for selected compounds
(IC50: 1.2–4.6mM) with limited butyrylcholinesterase inhibitory activity (IC50’s >160mM), indicating excellent
selectivity towards AChE (SI: 46 – >278). The compounds also showed considerable antioxidant ability,
similar to edaravone. In silico studies indicated that these compounds should cross the blood–brain bar-
rier, making them promising lead molecules in the development of anti-Alzheimer’s agents.
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Alzheimer’s disease (AD) is a progressive neurodegenerative dis-
order that is mainly prevalent in the older population (>65 years
of age)1–3. Approximately fifty million people are diagnosed with
dementia, with AD accounting for 60–70% of these cases4. The
disease can be characterised by an array of symptoms which
include; memory loss, cognitive impairment, behavioural and psy-
chiatric abnormalities3. Due to the complex and multifactorial
nature of AD, the exact aetiology of the disease is unknown.
Multiple pathways and hypotheses have been indicated in the
pathology of the disease such as the Ab cascade-, cholinergic-
and the oxidative stress hypotheses1,3,5.
Senile plaques are considered a pathological hallmark of AD.
The primary constituent of these senile plaques is Ab and are
believed to play a central role in the pathogenesis of the dis-
ease6,7. The amyloid cascade hypothesis suggests that one of the
main driving forces behind AD development is the buildup and
deposition of Ab peptide aggregation within the brain8,9.
Recently, it was discovered that the amyloid precursor protein
(APP) gene undergoes mutations that induce an increase in Ab
formation. The APP mutations are situated near the sites where
proteases, b and c-secretase, cleave the APP. These mutations
result in the favouring of the Ab1–40 and Ab1–42 peptide fragment
formation7,8,10. Ab1–40 and Ab1–42 are more inclined to self-aggre-
gate to form amyloid beta fibrils. With the persistent imbalance of
the production and clearance of the Ab fragments, the conse-
quential result is the genesis of insoluble senile plaques. These
senile plaques result in the blockage of parenchymal spaces
between neurons in the brain leading to eventual neuronal
cell death8,9.
The cholinergic hypothesis describes that the hydrolysis of the
neurotransmitter acetylcholine (ACh) by cholinesterases, acetyl-
cholinesterase (AChE) and butyrylcholinestrase (BuChE), leads to a
drastic decrease in ACh levels. The loss of cholinergic transmission
due to the decreased levels of ACh has been correlated with loss
of memory and cognitive ability11. AChE is the predominant
enzyme that hydrolyse ACh in the healthy brain12. The AChE
enzyme contains a pocket with two binding sites, the catalytic
anionic site (CAS) and peripheral anionic site (PAS). Interactions
with both these sites are crucial for the inhibition of AChE activity
and potential neuroprotective effects13. The PAS possesses a non-
cholinergic role that through protein–protein interactions, bind to
and promotes the formation and deposition of insoluble Ab fibrils
leading to neurotoxicity. Recent studies have shown that the
inhibition in the PAS did not only improve the memory in a trans-
genic APP/PS1 murine model, but also significantly stemmed the
amount of Ab plaques in the brain14–16.
Reactive oxygen species (ROS) are known to play a significant
role in the progression of neurodegenerative disorders such as
AD17–19. The most significant ROS include hydroxyl radicals, super-
oxide anions and peroxyl radicals19. As ROS begins to accumulate
and antioxidant levels begin to reduce, detrimental effects in the
brain begin to occur. This process is further increased with
aging17,19. The brain is especially susceptive to the neurotoxic
effects of ROS due to its high demand for oxygen as well as the
large amounts of peroxide susceptible lipid cells18. ROS have also
been observed to cause disruptions in neuronal cell integrity and
to modify and inactivate several proteins that are important for
glucose metabolism and ATP synthesis resulting in mitochondrial
dysfunction10,18. The occurrence of the neurotoxic effects of ROS
in the development of AD, coupled with the presence of Ab,
CONTACT Jacques Joubert jjoubert@uwc.ac.za School of Pharmacy, University of the Western Cape, Private Bag X17, Bellville, 7535, South Africa
Supplemental data for this article is available online at here.
 2020 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY
2020, VOL. 35, NO. 1, 1596–1605
https://doi.org/10.1080/14756366.2020.1801673
supports the role of oxidative stress in the pathogenesis of
AD18,20,21. Several lines of evidence have revealed a connection
between oxidative stress and Ab formation10,19,22. Ab exhibits the
ability to enhance the formation of ROS and vice versa22,23. Ab
produces ROS through the promotion of oxidative modification
and inhibition of important transmembrane transports systems
within the neuronal and glial cells, Ab-induced lipid peroxidation
and protein oxidation22,24,25. In addition, ROS also stimulate the
enhanced activity of proteases, b and c-secretase, which increases
the formation of Ab1–40 and Ab1–42
23.
At present, there are no therapeutic agents that are able to
reverse, halt or slow the progression of the disease and the cur-
rent options are only able to treat AD symptomatically2,11,26–28. All
of these treatments follow the much researched “one-molecule–-
one-target” drug discovery approach with minimal success.
Therefore, more researchers are exploring the development of
multi-target directed ligands (MTDL)26. MTDLs are conceived from
the molecular hybridisation of various pharmacophoric moieties
from recognised bioactive compounds. The MTDLs are designed
to interact with multiple targets involved in the multifactorial
pathogenesis of AD. The rational decision to combine these phar-
macophores results in greater selectivity for the targets of AD,
leads to fewer side effects and potentially improves the com-
pounds’ neuroprotective abilities29,30.
Edaravone (Figure 1(a)) is a potent free radical scavenger used
to treat acute cerebral infarction in Japan31. In addition, edaravone
has also exhibited beneficial neuroprotective effects in amyo-
trophic lateral sclerosis (ALS) and Parkinson’s disease animal mod-
els32. Edaravone’s neuroprotective effects are believed to be
caused by its ability to scavenge ROS. The decrease in ROS levels
in turn reduces oxidative stress and oxidative damage to neuronal
cells33,34. In previous studies, edaravone has demonstrated the
ability to attenuate Ab-induced oxidative stress and neurotoxicity,
inhibit Ab aggregation, disaggregate preformed Ab fibrils and
attenuate downstream pathologies including tau-hyperphosphory-
lation, neuroinflammation and neuronal cell loss31,35.
In search for potentially potent and selective AChE inhibitors,
benzyl pyridinium salts have been extensively researched (Figure
1(b))36–39 and N-benzyl pyridinium moieties have demonstrated
excellent activity against AChE. Previous research has found that
the best AChE inhibitory activity is reached when the N-benzyl
pyridinium moiety is bound to another privileged molecule, using
the MTDL strategy, to form a dual-site (PAS and CAS) binding
compound37,38. Substitutions, e.g. halogens and methyl groups, at
various positions on the benzyl group of the moiety has demon-
strated improved AChE inhibitory activity compared to an unsub-
stituted benzyl ring36,40.
Thus, we describe here the docking, synthesis and biological
evaluation of new edaravone-N-benzyl pyridinium hybrid com-
pounds (Figure 2). These compounds are expected to exhibit
strong dual-site AChE inhibitory activities and significant antioxi-
dant capacity, which could lead to promising MTDL neuroprotec-
tive effects.
2. Materials and methods
2.1. Chemistry
All the reagents used to synthesise the desired compounds were
acquired from Sigma-AldrichVR or Industrial Analytical (Pty) Ltd. All
the reagents were used without further purification. Solvents used
in the synthesis and purification of the compounds were obtained
from a variety of commercial sources. Thin-layer chromatography
(TLC) was used to monitor all reactions and was carried out on
0.20mm thick aluminium silica gel sheets (TLC silica gel 60 F245
Merck KGaA). Visualisation of the samples was achieved using UV
light (254 nm and 366 nm) and iodine vapours. Mobile phases
were prepared on a volume-to-volume basis. Infra-red spectra
were acquired using a Perkin Elmer Spectrum 400 spectrometer.
The IR spectrometer was equipped with a diamond attenuated
total reflectance (ATR) attachment. The spectra were then
acquired from PerkinElmer, Inc. Spectrum version 10.5.4 IR soft-
ware. The MS spectra of the compounds were acquired from a
Waters SYNAPT G2 high resolution mass spectrometer. The melt-
ing points of the samples were acquired using a Lasec Melting
Point SMP 10 apparatus and capillary tubes. Proton (1H) and car-
bon (13C) spectra were acquired using a Bruker Avance IIIHD
Nanobay 400MHz instrument that is equipped with a 5mm BBO
probe. Tetramethylsilane (TMS) was used as the internal standard
and deuterated dimethyl sulfoxide (DMSO-d6) as the deuterated
solvent. Chemical shifts (d) and coupling constants (J) were
reported in parts per million (ppm) and hertz (Hz) respectively.
The internal standard (d¼ 0 ppm) and DMSO-d6 (d¼ 2.5 ppm)
were used as the reference peaks. The multiplicities of the
respective signals were indicated using the following abbrevia-
tions: s – singlet, d – doublet, t – triplet, m – multiplet. The atom
numbering of the target compounds used for 1H NMR data are
depicted on each respective compound found in the supplemen-
tary data.
2.1.1. Synthesis of 4–(3-Methyl-5-oxo-4H-pyrazol-1-yl)-N-(pyri-
dine-4-ylmethyl)benzamide (3)
The 4-(aminomethyl)pyridine moiety was conjugated to the car-
boxylic group of 1 via HATU activational chemistry. One equiv.
edaravone-COOH (1) and four equiv. of N,N-diisopopylethylamine
(DIPEA) was stirred at room temperature for 20min. Thereafter,
the carboxylic acid of 1 was activated using the HATU activational
agent in a 1 equiv.:1.2 equiv. ratio in an appropriate quantity of
dimethylformamide (DMF). The mixture was stirred at room tem-
perature for 1 h and monitored using TLC (3 ethanol: 2 ethyl acet-
ate: 4 diethyl ether). Once the reaction was complete, 4-
(aminomethyl) pyridine (2) was added to the mixture and stirred
under reflux at 40–50 C for 1 h and monitored using TLC. Once
the reaction was complete, toluene was added to the mixture in a
ratio of 3 equiv. toluene: 1 equiv. DMF. The reaction was then
rotary evaporated until just off dry. The mixture was left to pre-
cipitate out overnight in a refrigerator. Finally, the precipitate was
filtered and washed with distilled water. The precipitate was
Figure 1. The two moieties combined to synthesise the novel MTDLs in this
study. (a) Edaravone. (b) R-substituted N-benzyl pyridinium. Figure 2. Edaravone-N-benzyl pyridinium hybrid compounds designed and eval-
uated in this study. R¼H, Br, F, Cl, or CH3.
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placed in a vacuum oven and allowed to dry rendering the
desired compound 3.
Physical data: Yield: 72.52%; light pink solid; mp: 234 C; Rf:
0.45; 1H NMR: (400MHz, DMSO-d6), dH: 9.10–9.13 (t, 1H, J¼ 5.60,
5.83, 11.43Hz, H – 12), 8.50–8.51 (d, 2H, J¼ 5.88Hz, H—16, 17),
7.95–7.98 (d, 2H, J¼ 8.68Hz, H—6, 10), 7.85–7.87 (d, 2H, J¼ 8.64,
H—7, 9). 7.30–7.32 (d, 2H, J¼ 5.76Hz, H—15, 18), 4–49-4.51 (s, 2H,
H—13), 2,13 (s, 3H, H—1); 13C NMR: (400MHz, DMSO-d6): 166.36,
149.98, 149.15, 128.66, 122.62, 120.10, 42.21, 14.70; IR: (FT-IR,
cm1): 3217, 3035, 1713, 1637; MS: (HR-ESIþ), [MþHþ], m/z: calcd.:
309.1273, found: 309.1347.
2.1.2. General procedure for the synthesis of compounds 5a–l
Compound 3 (1 equiv.) and 1.3 equiv. of the respective substi-
tuted benzyl bromide derivative (4) were dissolved and stirred
under reflux, at 40–50 C, in 5–6ml of DMF. The compounds were
monitored using TLC (3 ethanol: 2 ethyl acetate: 4 diethyl ether)
for 4–6 h. Once the reaction was complete, 3 equiv. toluene: 1
equiv. DMF was added. The mixture was then rotary evaporated
to dryness. Thereafter, 20ml of diethyl ether was added to the
dried mixture. The mixture was then left to precipitate out over-
night in a refrigerator. Thereafter, if solid, the precipitate was fil-
tered off and washed with diethyl ether. If the precipitate
exhibited a waxy/oily appearance the mixture was diluted in a
minimal amount of ethanol and transferred into a polytop. Finally,
the precipitate or waxy/oily substance was dried, rendering the
desired compounds 5a–l.
2.1.2.1. 1-Benzyl-4-(f[4–(3-methyl-5-oxo-4H-pyrazol-1-yl)phenyl]-
foramidogmethyl)pyridin-1-ium bromide (5a). Physical data:
Yield: 95.29%; light grey solid; mp: 225 C; 1H NMR: (400MHz,
DMSO-d6), dH 9.33–9.36 (t, 1H, J¼ 5.60, 5.72, 11.32 Hz H—12),
9.11–9.12 (d, 2H, J¼ 6.32Hz, H—16, 17), 8.06–8.07 (d, 2H,
J¼ 6.24Hz, H—15, 18), 7.97–7.99 (d, 2H, J¼ 8.60Hz, H—6, 10),
7.87–7.89 (d, 2H, J¼ 8.64Hz, H—7, 9), 7.43–7.53 (m, 5H, H—21, 22,
23, 24, 25), 5.83 (s, 2H, H—19), 4.72–4.74 (d, 2H, J¼ 5.28Hz, H—
13), 2.13 (s, 3H, H—1); 13C NMR: (400MHz, DMSO-d6): 166.68,
162.79,160.74, 159.84, 144.80, 134.87, 129.83, 129.72, 129.59,
129.23, 128.96, 128.84, 126.55, 119.36, 117.36, 63.14, 42.80, 17.19;
IR: (FT-IR, cm1): 3184, 3034, 1717,1639; MS: (HR-ESIþ), [M-Br]þ, m/
z: calcd.: 399.1815, found: 399.1820.
2.1.2.2. 1-[(2-Fluorophenyl)methyl]-4-(f[4–(3-methyl-5-oxo-4H-
pyrazol-1-yl)phenyl]foramidog methyl)pyridin-1-ium bromide
(5b). Physical data: Yield: 97.17%; black solid; mp: 191 C; 1H NMR:
(400MHz, DMSO-d6), dH: 9.33–9.36 (t, 1H, J¼ 5.72, 5.83, 11.55Hz,
H—12), 9.03–9.04 (d, 2H, J¼ 6.44Hz, H—16, 17), 8.06–8.08 (d, 2H,
J¼ 6.52Hz, H—15, 18), 7.87–8.00 (m, 4H, H—6, 7, 9, 10), 7.58–7.62
(t, 1H, J¼ 7.68, 7.56, 15.24, Hz, H—22), 7.51–7.55 (m, 1H, H—23),
7.34–7.35 (d, 1H, J¼ 1.88Hz, H—24), 7.30–7.32 (d, 1H, J¼ 7.96Hz,
H—25), 5.93 (s, 2H, H—19), 4.74–4.75 (d, 2H, J¼ 5.40Hz, H—13),
2.14 (s, 3H, H—1); 13C NMR: (400MHz, DMSO-d6): 166.69, 162.78,
162.20, 161.08, 145.01, 132.65, 132.57, 131.96, 128.83, 126.53,
125.81, 125.78, 121.87, 121.72, 117.37, 116.62, 116.41, 57.83, 42.84;
IR: (FT-IR, cm1): 3201, 3034, 1717, 1638; MS: (HR-ESIþ), [M-Br]þ,
m/z: calcd.: 417.1721found: 417.1719.
2.1.2.3. 1-[(3-Fluorophenyl)methyl]-4-(f[4–(3-methyl-5-oxo-4H-
pyrazol-1-yl)phenyl]foramidog methyl)pyridin-1-ium bromide
(5c). Physical data: Yield: 98.48%; brown solid; mp: 220 C; 1H
NMR: (400MHz, DMSO-d6), dH: 9.33–9.36 (t, 1H, J¼ 5.60, 5.83,
11.43Hz, H—12), 9.11–9.13 (d, 2H, J¼ 6.64Hz, H—16, 17),
8.07–8.08 (d, 2H, J¼ 6.56Hz, H—15, 18), 7.87–8.00 (m, 4H, H—6, 7,
9, 10), 7.48–7.54 (m, 1H, H—23), 7.45–7.48 (d, 1H. J¼ 10.2, H—21),
7.37–7.39 (d, 1H, J¼ 7.72Hz, H—25), 7.26–7.31 (m, 1H, H—24),
5.85 (s, 2H, H—19), 4.73–4.75 (d, 2H, J¼ 5.32, H—13), 2.14 (s,3H,
H—1); 13C NMR: (400MHz, DMSO-d6): 166.68, 163.88, 161.44,
160.89, 144.89, 137.26, 137.18, 131.91, 131.82, 128.84, 126.58,
125.48, 125.45, 119.39, 117.36, 116.87, 116.47, 62.34, 42.82, 17.18;
IR: (FT-IR, cm1): 3201, 3036, 1716, 1638; MS: (HR-ESIþ), [M-Br]þ,
m/z: calcd.: 417.1721, found: 417.1732.
2.1.2.4. 1-[(4-Fluorophenyl)methyl]-4-(f[4–(3-methyl-5-oxo-4H-
pyrazol-1-yl)phenyl]foramidog methyl)pyridin-1-ium bromide
(5d). Physical data: Yield: 87.13%; light grey solid; mp: 215 C; 1H
NMR: (400MHz, DMSO-d6), dH: 9.32–9.35 (t, 1H, J¼ 5.60, 5.80,
11.43HZ, H—12), 9.09–9.10 (d, 2H, J¼ 6.64Hz, H—16, 17),
8.05–8.07 (d, 2H, J¼ 6.48Hz, H—15, 18), 7.87–7.99 (m, 4H, H—6, 7,
9, 10), 7.61–7.64 (m, 2H, H—22, 25), 7.28–7.32 (t, 2H, J¼ 8.80,
17.60Hz, H—21, 25), 5.81 (s, 2H, H—19), 4.72–4.73 (d, 2H,
J¼ 5.44Hz, H—13), 2.13 (s, 3H, H—1); 13C NMR: (400MHz, DMSO-
d6): 166.67, 164.27, 161.82, 160.76, 144.72, 131.93, 131.85, 131.09,
131.06, 128.94, 128.83, 126.55, 117.36, 116.74, 116.53, 62.29, 42.81,
17.19; IR: (FT-IR, cm1): 3201, 3036, 1716, 1638; MS: (HR-ESIþ), [M-
Br]þ, m/z: calcd.: 417.1721, found: 417.1729.
2.1.2.5. 1-[(2-Chlorophenyl)methyl]-4-(f[4–(3-methyl-5-oxo-4H-
pyrazol-1-yl)phenyl]foramidog methyl)pyridin-1-ium bromide
(5e). Physical data: Yield: 96.53%; black solid; mp: 211 C; 1H NMR:
(400MHz, DMSO-d6), dH: 9.36–9.38 (t, 1H, J¼ 5.60, 5.72, 11.32Hz,
H—12), 9.00–9.02 (d, 2H, J¼ 6.32Hz, H—16, 17), 8.07–8.09 (d, 2H,
J¼ 6.28Hz, H—15, 18), 7.98–8.01 (d, 2H, J¼ 8.64Hz, H—6, 10),
7.88–7.90 (d, 2H, J¼ 8.68Hz, H—7, 9), 7.59–7.61 (d, 1H, J¼ 7.44Hz,
H—22), 7.47–7.54 (m, 3H, H—23, 24, 25), 5.97 (s, 2H, H—19),
4.76–4.77 (d, 2H, J¼ 5.32Hz, H—13), 2.13 (s, 3H, H—1); 13C NMR:
(400MHz, DMSO-d6): 166.71, 162.79, 161.17, 145.19, 133.77,
132.09, 131.98, 130.61, 129.58, 128.96, 128.84, 128.67, 126.42,
119.38, 117.37, 61.11, 42.83, 17.81; IR: (FT-IR, cm1): 3212, 3034,




(5f). Physical data: Yield: 21.31%; black solid mp: 228 C; 1H NMR:
(400MHz, DMSO-d6), dH: 9.30–9.33 (t, 1H, J¼ 5.60, 5.83, 11.43Hz,
H—12), 9.09–9.11 (d, 2H, J¼ 6.6 Hz, H—16, 17), 8.05–8.07 (d, 2H,
J¼ 6.44Hz, H—14, 18), 7.96–7.98 (d, 2H, J¼ 8.72Hz, H—6, 10),
7.87–7.89 (d, 2H, J¼ 8.76Hz, H—7,9), 7.69 (s, 1H, H—21), 7.47–7.52
(t, 3H, J¼ 13.62, 6.22, 19,84Hz, H—23, 24, 25), 5.81 (s, 2H, H—19),
4.73–4.74 (d, 2H, J¼ 5.40Hz, H—13), 2.13 (s, 3H, H—1); 13C NMR:
(400MHz, DMSO-d6): 166.69, 160.90, 144. 89, 137.00, 134.16,
131.62, 129.83, 129.31, 128.83, 128.05, 126.60, 62.31, 42.84, 14.62;
IR: (FT-IR, cm1): 3213, 3035, 1710, 1639; MS: (HR-ESIþ), [M-Br]þ,
m/z: calcd.:433.1425, found: 433.1430.
2.1.2.7. 1-[(2-Bromophenyl)methyl]-4-(f[4–(3-methyl-5-oxo-4H-
pyrazol-1-yl)phenyl]foramidog methyl)pyridin-1-ium bromide
(5g). Physical data: Yield: 94.2%; black solid; mp: 204 C; 1H NMR:
(400MHz, DMSO-d6), dH: 9.53–9.37 (t, 1H, J¼ 5.60, 5.83, 11.43Hz,
H—12), 8.98–9.00 (d, 2H, J¼ 6.52Hz, H—16, 17), 8.07–8.09 (d, 2H,
J¼ 6.40Hz, H—15, 18), 7.87–8.00 (m, 4H, H—6, 7, 9, 10), 7.76–7.78
(d, 1H, J¼ 7.60Hz, H—25), 7.49–7.53 (t, 1H, J¼ 7.06, 7.40, 14.46Hz,
H—22), 7.36–7.44 (m, 2H, H—23, 24), 5.94 (s, 2H, H—19),
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4.76–4.78 (d, 2H, J¼ 5.44, H—13), 2.13 (s, 3H, H—1); 13C NMR:
(400MHz, DMSO-d6): 166.71, 162.77, 161.21, 145.24, 133.91,
133.56, 132.04, 131.98, 129.18, 128. 96, 128.84, 126.41, 123.98,
63.17, 42.84, 14.62; IR: (FT-IR, cm1): 3217, 3034, 1711, 1638; MS:
(HR-ESIþ) [M-Br]þ, m/z: calcd.: 477.0920, found: 477.0928.
2.1.2.8. 1-[(3-Bromophenyl)methyl]-4-(f[4–(3-methyl-5-oxo-4H-
pyrazol-1-yl)phenyl]foramidog methyl)pyridin-1-ium bromide
(5h). Physical data: Yield: 17.73%; dark grey solid; mp: 230 C; 1H
NMR: (400MHz, DMSO-d6), dH: 9.30–9.33 (t, 1H, J¼ 5.60, 5.72,
11.32Hz, H—12), 9.09–9.10 (d, 2H, J¼ 6.4 Hz, H—16, 17), 8.05–8.07
(d, 2H, J¼ 6.32Hz, H—15, 18), 7.96–7.98 (d, 2H, J¼ 8.60Hz, H—6,
10), 7.87–7.89 (d, 2H, J¼ 8.64Hz, H—7, 9), 7.83 (s, 1H, H—21),
7.63–7.65 (d, 1H, J¼ 8.00Hz, H—23), 7.52–7.54 (d, 1H, J¼ 7.76Hz,
H—25), 7.39–7.54 (t, 1H, J¼ 7.74, 7.90, 15.64Hz, H—24), 5.80 (s,
2H, H—19), 4.73–4.74 (s, 2H, J¼ 5.36Hz, H—13), 2.13 (s, 3H, H—1);
13C NMR: (400MHz, DMSO-d6): 166.69, 160.89, 144.88, 137.24,
132.74, 132.15, 131.86, 128.83, 128.43, 126.60, 122.72, 62.26, 42.84;
IR: (FT-IR, cm1): 3216, 3035, 1711, 1638; MS: (HR-ESIþ), [M-Br]þ,
m/z: calcd.:477.0920, found: 477.0940.
2.1.2.9. 1-[(4-Bromophenyl)methyl]-4-(f[4–(3-methyl-5-oxo-4H-
pyrazol-1-yl)phenyl]foramidog methyl)pyridin-1-ium bromide
(5i). Physical data: Yield: 97.42%; black solid; mp: 190 C; 1H NMR:
(400MHz, DMSO-d6), dH: 9.33–9.36 (t, 1H, J¼ 5.95, 11.90Hz, H—
12), 9.08–9.10 (d, 2H, J¼ 6.80Hz, H—16, 17), 8.06–8.07 (d, 2H,
J¼ 6.64Hz, H—15, 18), 7.95–7.99 (m, 2H, H—6, 10), 7.89–7.87 (d,
2H, J¼ 8.88Hz, H—7, 9), 7.65–7.68 (d, 2H, J¼ 8.40Hz, H—22, 24),
7.48–7.50 (d, 2H, J¼ 8.44Hz, H—21, 25), 5.81 (s, 2H, H—8),
4.72–4.74 (d, 2H, J¼ 5.52Hz, H—13), 2.13 (s, 3H, H—1); 13C NMR:
(400MHz, DMSO-d6): 166.67, 162.77, 160.85, 144.84, 134.11,
132.64, 131.58, 128.96, 128.84, 126.56, 123.34, 62.32, 42.80; IR: (FT-
IR, cm1): 3217, 3034, 1715, 1638; MS: (HR-ESIþ), [M-Br]þ, m/z:
calcd.: 477.0920, found: 477.0943.
2.1.2.10 4-(f[4–(3-Methyl-5-oxo-4H-pyrazol-1-yl)phenyl]forami-
dogmethyl)-1–(2-methylphenyl)-pyridin-1-ium bromide (5j).
Physical data: Yield: 21.75%; light grey solid; mp: 194 C; 1H NMR:
(400MHz, DMSO-d6), dH: 9.34–9.37 (t, 1H, J¼ 5.60, 5.83, 11.43Hz,
H—12), 8.93–8.95 (d, 2H, J¼ 6.64Hz, H—16, 17), 8.06–8.08 (d, 2H,
J¼ 6.56Hz, H—15, 18), 7.98–8.00 (d, 2H, J¼ 8.80Hz, H—6, 10),
7.87–7.89 (d, 2H, J¼ 8.80Hz, H—7, 9), 7.20–7.37 (m, 3H, H—23, 24,
25), 7.12–7.14 (d, 1H, J¼ 7.52Hz, H—26), 5.88 (s, 2H, H—19),
4.75–4.76 (d, 2H, J¼ 5.40Hz, H—13), 2.29 (s, 3H, H—22), 2.13 (s,
3H, H—1); 13C NMR: (400MHz, DMSO-d6): 166.70, 162.77, 160.81,
144.98, 137.38, 132.82, 131.43, 129.87, 129.57, 128.95, 128.83,
127.20, 126.49, 117.37, 61.36, 42.81, 19.23, 17.19; IR: (FT-IR, cm1):




Physical data: Yield: 98.3%; black powder; mp: 212 C; 1H NMR:
(400MHz, DMSO-d6), dH: 9.31–9.34 (t, 1H, J¼ 5.60, 5.83, 11.43Hz,
H—12), 9.08–9.09 (d, 2H, J¼ 6.64Hz, H—16, 17), 8.04–8.06 (d, 2H,
J¼ 6.52Hz, H—15, 18), 7.96–7.98 (d, 2H, J¼ 8.88Hz, H—6, 10),
7.87–7.89 (d, 2H, J¼ 8.80Hz, H—7, 9), 7.33–7.35 (d, 1H, J¼ 5.24Hz,
H—21), 7.29–7.31 (t, 2H, J¼ 2.35, 7.40, 9.75 Hz, H—24, 25),
7.23–7.24 (d, 1H, J¼ 6.84Hz, H—26), 5.77 (s, 2H, H—19), 4.72–4.73
(d, 2H, J¼ 5.44Hz, H—13), 2.30 (s, 3H, H—23), 2.13 (s, 3H, H—1);
13C NMR: (400MHz, DMSO-d6): 166.68, 160.68, 144,76, 139.10, 134.
76, 130.46, 129.75, 129.63, 128.83, 126.52, 126.32, 63.19, 42.81,
21.38, 17.1; IR: (FT-IR, cm1): 3208, 3034,1716, 1638; MS: (HR-ESIþ),
[M-Br]þ, m/z: calcd.:413.1972, found: 413.1973.
2.1.2.12. 4-(f[4–(3-Methyl-5-oxo-4H-pyrazol-1-yl)phenyl]forami-
dogmethyl)-1–(4-methylphenyl)-pyridin-1-ium bromide (5l).
Physical data: Yield: 60.13%; light grey solid; mp: 230 C; 1H NMR:
(400MHz, DMSO-d6), dH: 9.30–9.33 (t, 1H, J¼ 5.60, 5.83, 11.43Hz,
H—12), 9.06–9.08 (d, 2H, J¼ 6.6 Hz, H—167, 17), 8.03–8.05 (d, 2H,
J¼ 6.52Hz, H—15, 18), 7.96–7.98 (d, 2H, J¼ 8.68Hz, H—6, 10),
7.86–7.89 (d, 2H, J¼ 8.76Hz, H—7, 9), 7.41–7.43 (d, 2H, J¼ 7.96Hz,
H—21, 26) 7.24–7.26 (d, 2H, J¼ 7.88Hz, H—22, 25), 5.76 (s, 2H,
H—19), 4.71–4.72 (d, 2H, J¼ 5.44Hz, H—13), 2.29 (s, 3H, H—24),
2.13 (s, 3H, H—1); 13C NMR: (400MHz, DMSO-d6):166.67, 160.64,
144.67, 139.89, 131.89, 130.24, 129.29, 128.82, 126.50, 63.01, 42.81,
21.21, 17.1; IR: (FT-IR, cm1): 3224, 3032, 1714, 1638; MS: (HR-
ESIþ), [M-Br]þ, m/z: calcd.: 413.1972, found: 413.1974.
2.2. Ache molecular docking studies
Molecular Operating Environment (MOE) 2018.10 software pack-
age41 was employed to predict the interactions and binding
modes of the novel compounds within the active site of TcAChE.
The co-crystallised structure of TcAChE with donepezil (PDB acces-
sion code: 1EVE) was acquired from the Protein Data Bank
(PDB)38. The following protocol was employed, as previously
described42, to simulate the orientation and binding interactions
of the test compounds. Firstly, the test compounds were drawn
using ChemSketch v2019.2.1 and saved as a mol files. Secondly,
the enzyme structures were inspected for missing atoms, bonds
and contacts. Thirdly, partial charges and hydrogens were added
using MOEs’ protonate 3D application. Fourthly, the ligands were
assembled employing the builder module in MOE and energy
minimisation (MMFF94x) was performed. Thereafter, the ligands
were docked, using the MOEdock application, within the AChE
active site. Finally, the retained best poses, as per their binding
affinity scores, were inspected visually and analysis of the interac-
tions within the active aromatic gorge of AChE was conducted. To
determine the accuracy of this docking protocol, the co-crystal-
lised ligand, was re-docked into the AChE active site. This proced-
ure was repeated three times and the best ranked solution
exhibited an RMSD value of less than 2.0 Å from the position of
the co-crystallised ligand. The RMSD value in this case is smaller
than 2.0 Å indicating that the docking protocol is capable of
accurately predicting the binding orientation of the co-crystallised
ligand43. This protocol was thus deemed to be suitable for the
docking of inhibitors into the active site model of AChE.
2.3. Pharmacological evaluation studies
2.3.1. Cholinesterase inhibition assay
A modified Ellman’s method was employed to determine the ChE
inhibitory activities of the synthesised compounds44. eeAChE,
eqBuChE, 5,50-dithiobis-(2-nitrobenzoic acid) (DTNB, commonly
known as Ellman’s reagent), S-butrylthiocholine iodide (BTCI), ace-
tylthiocholine iodide (ATCI) and donepezil were purchased from
Sigma-AldrichVR . eeAChE, eqBuChE, DTNB, BTCI and ATCI were
diluted with a buffer solution (tris hydrochloride (50mM), pH 8).
Each well of a 96 well plate, contained the following; 148 mL of
1.5mM DTNB, 50 mL of either 0.22 U/ml eeAChE or 0.12 U/ml
eqBuChE and 2 mL of either test compound, control (donepezil) or
blank [dimethyl sulfoxide (DMSO)]. The test compounds and con-
trol were dissolved in DMSO and added to the well to yield
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various concentrations (1000mM, 100 mM, 10 mM, 1 mM, 0.1mM and
0.01mM). The quantity of DMSO per well accumulated to below
0.01%45. Each concentration of test compound and control was
conducted in triplicate to ensure consistent results. The well-plates
were then incubated at 25 C for 10min. Thereafter, 30 mL of
either the ATCI or BTCI substrate was added to each well. The
plate was then placed inside a Rayto 6500 spectrometer and the
absorbance was read at 405 nm every 45 s for 5min. The percent-
age activity was calculated using the following equation: [(absorb-
ance of blank absorbance of test compounds)/absorbance of
blank  100)]. All data analysis was conducted on GraphPad Prism
version 8.2.1 for Mac OS, GraphPad Software (San Diego, CA, USA)
2.3.2. Antioxidant assay
Antioxidant activity was studied with the DPPHþ free radical scav-
enging assay46,47. DPPHþ and trolox were purchased from Sigma-
AldrichVR . The following method was employed, as previously
described48, to determine the antioxidant activity of the test com-
pounds. Each well of a 96 well plate, contained the following:
180 mL of 0.12mM DPPHþ dissolved in methanol and 20mL of
either test compound, control (trolox) or blank (DMSO). The test
compounds and control were dissolved in DMSO and added to
the well to yield various concentrations (1000 mM, 100 mM, 10mM,
1 mM and 0.1mM). Each concentration of test compound and con-
trol was conducted in triplicate to ensure consistent results. The
well plate was incubated at 25 C for 30min within a dark space.
A change of colour from dark purple to light yellow was observed.
The quantity of DMSO per well accumulated to below 0.01%45.
The plate was then placed inside a Rayto 6500 spectrometer and
the absorbance was read at 517 nm three times to ensure statis-
tical viability. The percentage activity was calculated using the fol-
lowing equation: [(absorbance of blank absorbance of test
compounds)/absorbance of blank  100)]. All data analysis was
conducted on GraphPad Prism version 8.2.1 for Mac OS, GraphPad
Software (San Diego, California, USA).
2.4. In silico blood–brain permeability predictions
An in silico model was used to determine the blood–barrier per-
meability of the synthesised compounds. The BBB predictor used
can be found on an intergrade cloud computing server called
AlzPlatform49. The BBB predictor was designed to determine
whether a ligand is permeable across the blood brain barrier
(BBBþ) or not (BBB). The BBB predictor was developed by apply-
ing the LiCABEDS and support vector machine (SVM) algorithms
on four types of fingerprints of 1593 reported compounds50–52.
The BBB predictor software employed is available at http://www.
cbligand.org/BBB/.
3. Results and discussion
Previous studies have shown that molecules that contain the N-
benzyl pyridinium moiety interact with the CAS of the AChE
enzyme36,37,40. Therefore, to determine if the edaravone portion of
the hybrid molecules would exhibit the proposed interactions
with the PAS as well as potential interactions exhibited by the N-
benzyl pyridinium moiety with the CAS, molecular docking studies
were performed. The molecular docking studies were conducted
using the Molecular Operating Environment (MOE) 2018.10 soft-
ware package53. The co-crystallised structure of TcAChE with
donepezil (PDB accession code: 1EVE)38 was utilised to establish
the starting model for AChE active site docking54. The findings
from these studies were then used to rationalise the synthesis and
evaluation of these compounds as potential MTDLs.
Results show that the majority of the hybrid compounds
exhibit potential interactions with important conserved residues
within the PAS site (Figures 3 and 4, and Supplementary Material).
In general, the compounds interacted with a combination of
important residues within the PAS, which included Trp 279 and
Tyr 33440,55. The compounds were also observed in close proxim-
ity to Arg 289. The Arg 289 residue is found in site I that is part of
one of the four putative binding sites within the PAS that was
shown to play an important role in Ab formation38. It has also pre-
viously been reported that Trp 279 plays a role in Ab forma-
tion54,56,57. These findings support the hypothesis that the
edaravone-N-benzyl pyridinium hybrid compounds could inhibit
AChE and significantly reduce the formation of AChE induced
Ab plaques.
In general, the hybrid compounds exhibited interactions with
the AChE mid-gorge recognition site residues Phe 330 and Phe
331 (Figures 3 and 4, and Supplementary Material)55. These inter-
actions are p–p interactions with the pyridinium ring and the car-
bon linker between the pyridinium ring and amide. It has also
previously been observed that the interaction between the pyridi-
nium ring and Phe 330 leads to stabilisation in the orientation of
a compound. This in turn, increases the probability for an
Figure 3. The active site cavity of AChE exhibiting the binding and interactions
of representative compound 5f (Scheme 1). (a) Two-dimensional (2D) representa-
tion of the docked compound 5f. The close proximity of the Arg 289 residue to
edaravone’s pyrazoline ring can be observed. (b) Three-dimensional (3D) repre-
sentation of the docked compound 5f, showing the orientation and positing of
5f within the AChE active site cavity.
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interaction with Trp 279 within the PAS37. The benzyl moiety of
the hybrid molecules was mainly found to interact with the resi-
due Trp 84 within the CAS55. Trp 84 is a key residue found within
the CAS and is responsible for the molecular recognition of cat-
ionic substrates in cholinesterases. Previous studies have shown
that the replacement of residue Trp 84 with alanine caused a dras-
tic decrease in human AChE’s ability to hydrolyse acetylthiocho-
line57. Interactions were also observed with His 440, a residue of
the catalytic triad found in the CAS and with Glu119, found in the
oxyanion site of the CAS. All these residues play a variable role in
the inhibitory activity of AChE55. From these results, it is clear that
the majority of the hybrid compounds exhibit similar orientational
and positional conformations within the AChE active site. The only
exception was found in compound 5i (Scheme 1 and
Supplementary Material) in that its most stable conformations
were flipped within TcAChE active site. The pyrazoline of the edar-
avone moiety in 5i interacted with Trp 84 through H–p stacking
and the pyridinium ring interacted with Trp 279 through p–p
stacking as well as H–p stacking. The intermediate 3, lacking the
benzyl moiety (Scheme 1 and Supplementary Material), interacts
with residues Phe 288 and Trp 84 present in the mid-gorge and
CAS respectively, and is not able to travers into the PAS of the
AChE active site. This indicates the potential importance of the
benzyl moiety for optimal dual site binding AChE inhibitory activ-
ity in these compounds. These results therefore indicate that the
docked compounds could exhibited the potential to act as dual-
site AChE inhibitors.
The synthesis of the novel MTDLs was carried out in two steps
(Scheme 1). Firstly, an amide intermediate (3) was formed by
reacting edaravone-COOH (1) with 4-(aminomethyl) pyridine (2)
via 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridi-
nium-3-oxid hexafluoro-phosphate (HATU) activational chemistry.
Thereafter, the final edaravone-N-benzyl pyridinium derivatives
(5a–5l), containing the pyridinium moiety, were synthesised via N-
benzylation of compound 3 with benzyl bromide containing vari-
ous substitutions (H, Br, F, Cl or CH3) at different positions of the
benzene ring.
Analytical instruments and techniques, described in the experi-
mental section, were employed for structural elucidation of the
synthesised compounds. All of the protons and carbons of the
aromatic groups, CH2 groups and CH3 moiety of the pyrazoline
ring, were observed for all the final compounds and exhibited
similar peaks on the 1H- and 13C-NMR spectra (Supplementary
Material). The only variance in NMR peaks were as a result of the
different functional group substitutions on the benzyl moiety. The
formation of the positively charged nitrogen of the pyridinium
group in 5a–5l, can be observed by a shift of the pyridine 1H
NMR doublet peaks from  8.5 ppm and 7.3 ppm to 9.1 ppm
and 8.0 ppm respectively when compared to the NMR of inter-
mediate 3. HRMS also confirmed the molecular masses and iden-
tity of the synthesised compounds. Refer to the supplementary
material for all NMR spectra and a complete discussion on NMR
and HRMS results.
Edaravone is known to exist in different neutral tautomeric
forms58. In all 1H NMR spectra where DMSO-d6 was used add-
itional peaks, visible at d¼ 5.4 ppm and 11.7 ppm, were observed
suggesting that the novel synthesised compounds may also exist
in different tautomeric states (Figures 5 and 6, and Supplementary
Material). The peaks, at d¼ 5.4 ppm and d¼ 11.7 ppm, were found
to belong to the respective CH-group and NH-group of the amine
tautomer portion of the edaravone of the synthesised com-
pounds59. In previous research, it has been found that the amine
tautomer of edaravone may be more stable in aprotic polar sol-
vents such as DMSO compared to the keto tautomer59,60. The
NMR experiment was repeated using the protic polar solvent,
methanol-d4. Using this solvent system, the keto tautomer was
Figure 4. The active site cavity of AChE exhibiting the binding and interactions
of representative compound 5c (Scheme 1). (a) 2 D representation of the docked
compound 5c. Interactions with Trp 279 (PAS) and Trp 84 (CAS) can be observed.
(b) 3D representation of the docked compound 5c, showing the orientation and
positing of 5c within the AChE active site cavity.
Scheme 1. Synthesis pathway of the edaravone-N-benzyl pyridinium derivatives 5a–5l. Reagents and conditions: (i) HATU, DMF, DIPEA, 2 h, stirring under reflux. (ii)
DMF, stirring under reflux, 4–6 h at 40–50 C. (1) Edaravone-COOH, (2) 4-(aminomethyl) pyridine, (4) R-benzyl bromide derivatives.
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found to be more stable as no peaks were present at d¼ 5.4 ppm
and d¼ 11.7 ppm (Figure 6). This finding is in accordance to previ-
ous research as it has been found that the enol and keto tauto-
meric forms are both found within this solvent system. In
addition, the keto tautomer was found to be the predominant of
the two tautomeric forms in methanol61. The enol tautomer 1H
NMR peak for the CH-group at d ¼ 6.2 ppm62 was not present
and further confirms the presence of the keto tautomer within the
methanol-d4 solvent system. The formation of the edaravone tau-
tomers are dependent on certain solvation effects and electro-
static interactions between the solvent and molecule and further
studies are to be conducted to explore the tautomeric nature of
these hybrid molecules. Based on the data in this study, the keto
tautomer of these hybrid molecules seems to be more stable in
polar protic solvents whereas its amine tautomeric form is more
stable in polar aprotic solvents. As the biological evaluations on
these compounds were carried out in protic environments it is
expected that the keto tautomer will be the predominant form
present. The effects of the different tautomers on the biological
profile of these compounds should therefore be taken into consid-
eration for future pharmaceutical development.
The inhibitory activities of the synthesised compounds were
evaluated using eeAChE (electric eel) and eqBuChE (equine serum)
according to a modified method of Ellman44. Donepezil, a known
potent ChE inhibitor, was used as the reference compound for
both assays. This reference compound was chosen as the structure
of donepezil contains similarities to the N-benzyl pyridinium moi-
ety of the synthesised compounds. Compounds 5b–5g exhibited
some of the best inhibitory activities (Table 1). These compounds
have either a fluorine or chlorine substituted at various positions
of the benzyl moiety and exhibited IC50 values between 1.2 and
4.6mM. It can be deduced that smaller and more electronegative
substitutions, such as fluorine or chlorine, in comparison to larger
substitutions, such as bromine (5h–5j) or methyl (5g–5i), is
preferred as it results in superior inhibitory activity (Table 1). The
majority of the final compounds also exhibited improved activity
compared to the unsubstituted benzyl moiety of 5a.
In addition, all the compounds with substituents in the ortho
position of the benzyl ring (5b, 5e, 5g, 5j) exhibited the highest
inhibitory activities when compared to their meta and para coun-
terparts. This finding is similar to that reported in previous stud-
ies37,66. The superior activity observed for 5a–5l when compared
to intermediate 3, could be due to the increase in the length of
the molecule. Molecular modelling corresponds with this observa-
tion in that 3 is too short to interact with both the PAS and CAS
Figure 5. Two major tautomeric forms of the edaravone-N-benzyl pyridinium hybrid compounds and their respective 1H NMR chemical tautomeric shifts in deuter-
ated solvents.
Figure 6. Overlaid 1H NMR spectra of compound 5g in methanol-d4 (blue) and DMSO-d6 (red). (a) Singlet that represents the CH-group of the amine tautomer.
Table 1. In silico BBB predictions and IC50 values (mM) of the test compounds
and controls for eeAChE, eqBuChE, and DPPHþ.
Compound R… . AChE BuChE SI AChEa DPPHþ BBB predictionb
3 – >100 >1000 n.d. 12.5 0.108
5a H 30 >1000 >33 22.9 0.081
5b 2-F 1.2 >1000 >83 28.8 0.068
5c 3-F 4.6 926 201 25 0.064
5d 4-F 3.6 >1000 >278 11.5 0.064
5e 2-Cl 1.9 890 468 13.8 0.060
5f 3-Cl 3.3 891 270 13.1 0.055
5g 2-Br 3.5 160 46 19 0.055
5h 3-Br >100 mM >1000 n.d. 13.3 0.062
5i 4-Br 11.5 >1000 >87 18.1 0.056
5j 2-CH3 19.9 630 32 9.5 0.056
5k 3-CH3 69.1 >1000 >15 27.5 0.080
5l 4-CH3 95.5 >1000 >11 14.5 0.077
1 – n.d. n.d. n.d. 45.7 –
Donepezilc – 0.006 7.14 1252 – –
Trolox – n.d. n.d. n.d. 13.1 –
Edaravoned – – – – – –
aAChE selectivity index¼ IC50(eqBuChE)/IC50(eeAChE).
bA value higher than 0.02 is predicted to cross the BBB using AlzPlatform’s inter-
grade cloud computing server49,63.
cIC50 values of donepezil reported by reference [64].
dIC50 values of edaravone reported by reference [65].
n.d.: not determined.
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of the AChE active site. This also confirms the importance of the
N-benzyl pyridinium group for optimal AChE inhibitory activity
within these compounds.
Compounds 5a–5l also exhibited highly selective AChE inhibi-
tory activity over BuChE (Table 1, SI:11 – >278). It can be specu-
lated that the poor BuChE inhibitory results exhibited by all the
compounds are due to the phenyl ring of edaravone and the pyri-
dinium moiety exhibiting p–p interactions with the aromatic resi-
dues of AChE but are not able to exhibit similar interactions with
BuChE’s aliphatic and/or aromatic residues67,68. The N-benzyl pyri-
dinium moiety presents a similar structure to donepezil’s benzyl-
pyridine moiety69. Therefore, the high selectivity of the hybrid
compounds for AChE compared to BuChE was expected.
Selectivity to AChE is advantageous as it has been shown to result
in lower incidences of cholinergic side effects and wider thera-
peutic indices compared to non-selective cholinesterase inhibi-
tors70. Most of the hybrid compounds exhibited proficient AChE
inhibitory activity when compared to previously designed, AChE
acting MTDLs30.
The 2,2-diphenyl-1-picrylhydrazyl (DPPHþ) assay was employed
to determine the antioxidant ability of the synthesised com-
pounds. Trolox, a known potent antioxidant, was used as the ref-
erence compounds for this assay71. Compounds 3, 5d–j and 5l
(IC50: 9.5–19 mM) exhibited similar or greater antioxidant activity
when compared to the control, Trolox (IC50 ¼ 13.1mM). In add-
ition, these compounds retained the antioxidant activity of edara-
vone (IC50 ¼ 4.7mM)65. Compound 5j had the best IC50 of 9.5mM.
The rest of the compounds within the series exhibited greater
antioxidant activity compared to 1. These results correspond with
previous literature in that a large lipophilic substitution on the 4-
position of the phenyl ring of the edarvone moiety improves its
antioxidant activity when compared to a smaller carboxylic group
on the 4-position of the phenyl ring of the edaravone
structure58,72,73.
Potential AD therapeutic agents are required to cross the
blood–brain barrier (BBB) to act in the CNS. Therefore, an in silico
model49,63 was used to determine the blood–barrier permeability
of the synthesised compounds. The BBB permeability prediction
score represents the compounds ability to cross the BBB. A thresh-
old score of over 0.02 is considered that the compounds are BBB
permeable (BBBþ) and a score below 0.02 is considered that the
compounds are BBB impermeable (BBB). The results are shown
in Table 1. All the compounds exhibit scores of above 0.02 and
are therefore predicted to effectively cross the BBB.
4. Conclusions
The main goal of this study was to design and synthesise a novel
series of multi-target directed edaravone-N-benzyl pyridinium
hybrid compounds that exhibit cholinesterase inhibitory activity
and significant antioxidant ability. The molecular modelling results
showed that these compounds should be able to form significant
interactions within the PAS and CAS of the AChE active site, which
in turn should lead to notable inhibitory activities. The in vitro
cholinesterase results indicated excellent selective AChE inhibitory
activity. Compounds 5b–g demonstrated the best AChE inhibitory
activity showing that smaller substitutions, e.g. fluorine and chlor-
ine, especially in the ortho benzyl position is important for AChE
inhibitory activity. Compounds 5d–j and 5l exhibited potent anti-
oxidant activity that was comparable to trolox and edaravone. In
silico blood–brain barrier evaluations predicted that all these
hybrid compounds should cross the BBB. Compound 5d–g pre-
sented as the most promising MTDL candidates against AD. These
compounds exhibited excellent selective AChE inhibitory activities
(IC50: 1.9–3.6mM), promising antioxidant abilities (IC50: 11.5–19mM)
and are predicted to cross the BBB. Further exploration of these
compounds’ abilities to exhibit Ab inhibitory activity, neuroprotec-
tion and their pharmacokinetic- and toxicity profiles are
recommended.
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